Performance of the Glucose Management Indicator (GMI) in Type 2 Diabetes

• Published in: Clinical chemistry (Baltimore, Md.) Md.), 2023-04, Vol.69 (4), p.422-428
• Main Authors: Fang, Michael, Wang, Dan, Rooney, Mary R, Echouffo-Tcheugui, Justin B, Coresh, Josef, Aurora, R Nisha, Punjabi, Naresh M, Selvin, Elizabeth
• Format: Article
• Language: English
• Subjects: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemia - diagnosis; Male; Middle Aged; Prospective Studies; Young Adult
• ISSN: 0009-9147; 1530-8561
• DOI: 10.1093/clinchem/hvac210

Abstract Background The glucose management indicator (GMI) is an estimated measure of hemoglobin A1c (HbA1c) recommended for the management of persons with diabetes using continuous glucose monitoring (CGM). However, GMI was derived primarily in young adults with type 1 diabetes, and its performance in patients with type 2 diabetes is poorly characterized. Methods We conducted a prospective cohort study in 144 adults with obstructive sleep apnea and type 2 diabetes not using insulin (mean age: 59.4 years; 45.1% female). HbA1c was measured at the study screening visit. Participants simultaneously wore 2 CGM sensors (Dexcom G4 and Abbott Libre Pro) for up to 4 weeks (2 weeks at baseline and 2 weeks at the 3-month follow-up visit). GMI was calculated using all available CGM data for each sensor. Results Median wear time was 27 days (IQR: 23–29) for the Dexcom G4 and 28 days (IQR: 24–29) for the Libre Pro. The mean difference between HbA1c and GMI was small (0.12–0.14 percentage points) (approximately 2 mmol/mol). However, the 2 measures were only moderately correlated (r = 0.68–0.71), and there was substantial variability in GMI at any given value of HbA1c (root mean squared error: 0.66–0.69 percentage points [7 to 8 mmol/mol]). Between 36% and 43% of participants had an absolute difference between HbA1c and GMI ≥0.5 percentage points (≥5 mmol/mol), and 9% to 18% had an absolute difference >1 percentage points (>11 mmol/mol). Discordance was higher in the Libre Pro than the Dexcom G4. Conclusions GMI may be an unreliable measure of glycemic control for patients with type 2 diabetes and should be interpreted cautiously in clinical practice. Clinicaltrials.gov Registration Number: NCT02454153.